Oda S, Fujiwara R, Kutsuno Y, Fukami T, Itoh T, Yokoi T, et al. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Drug Metab Dispos. 2015;43:812-8 pubmed publisher

Tamura D, Saito T, Murata K, Kawashima M, Asano R. Celecoxib exerts antitumor effects in canine mammary tumor cells via COX‑2‑independent mechanisms. Int J Oncol. 2015;46:1393-404 pubmed publisher

Majcher A, Lewandrowska A, Herold F, Stefanowicz J, Słowiński T, Mazurek A, et al. A method for rapid screening of interactions of pharmacologically active compounds with albumin. Anal Chim Acta. 2015;855:51-9 pubmed publisher

Nagata N, Niikura R, Sekine K, Sakurai T, Shimbo T, Kishida Y, et al. Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: a case-control study. J Gastroenterol Hepatol. 2015;30:292-8 pubmed publisher

Lee C, Shin Y, Nam M, Jeong K, Lee J. A new analytical method to determine non-steroidal anti-inflammatory drugs in surface water using in situ derivatization combined with ultrasound-assisted emulsification microextraction followed by gas chromatography-mass spectrometry. Talanta. 2014;129:552-9 pubmed publisher

Kutsuno Y, Itoh T, Tukey R, Fujiwara R. Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice. Drug Metab Dispos. 2014;42:1146-52 pubmed publisher

Slobodin G, Rosner I. Indemonstrable axial spondyloarthritis: does it exist?. Isr Med Assoc J. 2013;15:780-1 pubmed

Ellerkamp V, Lieber J, Nagel C, Wenz J, Warmann S, Fuchs J, et al. Pharmacological inhibition of beta-catenin in hepatoblastoma cells. Pediatr Surg Int. 2013;29:141-9 pubmed publisher

Takahashi J, Kobayashi H, Wakabayashi S, Deguchi M, Ito H, Mogami Y, et al. The effect of a prostaglandin E1 derivative on the symptoms and quality of life of patients with lumbar spinal stenosis. J Orthop Sci. 2013;18:208-15 pubmed publisher

Yamaoka T, Azukizawa H, Tanemura A, Murota H, Hirose T, Hayakawa K, et al. Toxic epidermal necrolysis complicated by sepsis, haemophagocytic syndrome, and severe liver dysfunction associated with elevated interleukin-10 production. Eur J Dermatol. 2012;22:815-7 pubmed publisher

Sampaziotis F, Brais R, Griffiths W. A case of acute liver failure due to etodolac. Br J Clin Pharmacol. 2013;75:1156-7 pubmed publisher

Surdyk K, Sloan D, Brown S. Renal effects of carprofen and etodolac in euvolemic and volume-depleted dogs. Am J Vet Res. 2012;73:1485-90 pubmed publisher

Hasegawa K, Kawamura K, Kato R, Komiyama S, Kaneko C, Udagawa Y. The effects of the selective cyclooxygenase-2 inhibitor on endometrial cytological findings in uterine endometrial cancer patients. Acta Cytol. 2012;56:394-400 pubmed publisher

Inoue N, Ito S, Nogawa M, Tajima K, Kyoi T. Etodolac blocks the allyl isothiocyanate-induced response in mouse sensory neurons by selective TRPA1 activation. Pharmacology. 2012;90:47-54 pubmed publisher

Imamura H, Hata J, Iida A, Manabe N, Haruma K. Evaluating the effects of diclofenac sodium and etodolac on renal hemodynamics with contrast-enhanced ultrasonography: a pilot study. Eur J Clin Pharmacol. 2013;69:161-5 pubmed publisher

Ozturk V, Ertas M, Baykan B, Sirin H, Ozge A. Efficacy and safety of 400 and 800 mg etodolac vs. 1,000 mg paracetamol in acute treatment of migraine: a randomized, double-blind, crossover, multicenter, phase III clinical trial. Pain Pract. 2013;13:191-7 pubmed publisher

Miyazawa K, Takahashi Y, Morita N, Moriyama M, Kosaka T, Nishio M, et al. Cyclooxygenase 2 and prostaglandin E2 regulate the attachment of calcium oxalate crystals to renal epithelial cells. Int J Urol. 2012;19:936-43 pubmed publisher

Ito S, Tajima K, Nogawa M, Inoue N, Kyoi T, Takahashi Y, et al. Etodolac, a cyclooxygenase-2 inhibitor, attenuates paclitaxel-induced peripheral neuropathy in a mouse model of mechanical allodynia. J Pharmacol Exp Ther. 2012;342:53-60 pubmed publisher

Nozawa Y, Sato A, Piao H, Morioka T, Narita I, Oite T. The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I2 analog on the progression of sclerotic glomerulonephritis in rats. Clin Exp Nephrol. 2012;16:221-30 pubmed publisher

Pareek A, Chandurkar N, Gupta A, Desai Y, Kumar S H, Swamy A, et al. Comparative evaluation of efficacy and safety of etodolac and diclofenac sodium injection in patients with postoperative orthopedic pain. Curr Med Res Opin. 2011;27:2107-15 pubmed publisher

Hazut O, Shaashua L, Benish M, Levi B, Sorski L, Benjamin B, et al. The effect of ?-adrenergic blockade and COX-2 inhibition on healing of colon, muscle, and skin in rats undergoing colonic anastomosis. Int J Clin Pharmacol Ther. 2011;49:545-54 pubmed

Mehta P, Lukacs M, Abraham S. Normal in the blood, abnormal in the urine. QJM. 2012;105:1001-2 pubmed

Murata S, Adachi M, Kioi M, Torigoe S, Ijichi K, Hasegawa Y, et al. Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase. Anticancer Res. 2011;31:2893-8 pubmed

El Hay S, Colyer C, Hassan W, Shalaby A. Spectrofluorimetric determination of etodolac, moxepril HCl and fexofenadine HCl using europium sensitized fluorescence in bulk and pharmaceutical preparations. J Fluoresc. 2012;22:247-52 pubmed publisher

Adhim Z, Matsuoka T, Bito T, Shigemura K, Lee K, Kawabata M, et al. In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer. 2011;105:393-402 pubmed publisher

Nakamura Y, Takemoto A, Muto M. Acute generalized exanthematous pustulosis due to etodolac in a patient with an iliopsoas muscle abscess. Acta Derm Venereol. 2011;91:589-90 pubmed publisher

Inoue N, Nogawa M, Ito S, Tajima K, Kume S, Kyoi T. The enantiomers of etodolac, a racemic anti-inflammatory agent, play different roles in efficacy and gastrointestinal safety. Biol Pharm Bull. 2011;34:655-9 pubmed

Abd Elbary A, Tadros M, Alaa Eldin A. Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets. AAPS PharmSciTech. 2011;12:485-95 pubmed publisher

Goldfarb Y, Sorski L, Benish M, Levi B, Melamed R, Ben Eliyahu S. Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. Ann Surg. 2011;253:798-810 pubmed publisher

Hasegawa K, Torii Y, Ishii R, Oe S, Kato R, Udagawa Y. Effects of a selective COX-2 inhibitor in patients with uterine endometrial cancers. Arch Gynecol Obstet. 2011;284:1515-21 pubmed publisher

Akagi Y, Nio Y, Shimada S, Aoyama T. Influence of nonsteroidal anti-inflammatory drugs on the antiplatelet effects of aspirin in rats. Biol Pharm Bull. 2011;34:233-7 pubmed

Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y, et al. Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin Cancer Res. 2011;17:3803-11 pubmed publisher

Santra G, Sarkar R, Phaujdar S, Banerjee S, Siddhanta S. Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J. 2010;51:883-7 pubmed

Ibrahim M, El Nabarawi M, El Setouhy D, Fadlalla M. Polymeric surfactant based etodolac chewable tablets: formulation and in vivo evaluation. AAPS PharmSciTech. 2010;11:1730-7 pubmed publisher

Tirunagari S, Derry S, Moore R, McQuay H. Single dose oral etodolac for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009;:CD007357 pubmed publisher

Dvornik D. Tissue selective inhibition of prostaglandin biosynthesis by etodolac. J Rheumatol Suppl. 1997;47:40-7 pubmed

Benet L. Pharmacokinetics of sustained-release etodolac. Rheumatol Int. 1993;13:S3-5 pubmed

Brocks D, Jamali F. Etodolac clinical pharmacokinetics. Clin Pharmacokinet. 1994;26:259-74 pubmed

Veys E. Clinical performance of etodolac in patients with osteoarthritis and rheumatoid arthritis. Eur J Rheumatol Inflamm. 1994;14:23-7 pubmed

Humber L. Etodolac: the chemistry, pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid. Med Res Rev. 1987;7:1-28 pubmed

Lynch S, Brogden R. Etodolac. A preliminary review of its pharmacodynamic activity and therapeutic use. Drugs. 1986;31:288-300 pubmed

Karbowski A. A global safety evaluation of etodolac. Clin Rheumatol. 1989;8 Suppl 1:73-9 pubmed

Lanza F, Arnold J. Etodolac, a new nonsteroidal anti-inflammatory drug: gastrointestinal microbleeding and endoscopic studies. Clin Rheumatol. 1989;8 Suppl 1:5-15 pubmed

Zvaifler N. A review of the antiarthritic efficacy and safety of etodolac. Clin Rheumatol. 1989;8 Suppl 1:43-53 pubmed

Brater D, Lasseter K. Profile of etodolac: pharmacokinetic evaluation in special populations. Clin Rheumatol. 1989;8 Suppl 1:25-35 pubmed

Pena M. Etodolac: analgesic effects in musculoskeletal and postoperative pain. Rheumatol Int. 1990;10 Suppl:9-16 pubmed

Bacon P. Etodolac: efficacy in osteoarthritis and effects on chondrocyte function. Rheumatol Int. 1990;10 Suppl:3-7 pubmed

Balfour J, Buckley M. Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs. 1991;42:274-99 pubmed